A screening
>>> for most men since it is largely non-specific. That test is what leads
>>> to the biopsies. Less screening = fewer biopsies = less revenue.
>>>
>>> Tim Morken
>>>
>>>
>>>
>>> -Original Message-
>>> From:
: histonet-boun...@lists.utsouthwestern.edu
[mailto:histonet-boun...@lists.utsouthwestern.edu] On Behalf Of Daniel Schneider
Sent: Tuesday, April 10, 2012 11:22 AM
To: Histonet
Subject: [Histonet] In House Labs in WSJ
The Wall Street Journal served up a timely article for us.
You'll see both sides o
> biopsies. Less screening = fewer biopsies = less revenue.
> >
> > Tim Morken
> >
> >
> >
> > -Original Message-
> > From: histonet-boun...@lists.utsouthwestern.edu [mailto:
> histonet-boun...@lists.utsouthwestern.edu] On Behalf Of Daniel Schneider
>
term.
>> There is a recommendation out there to stop PSA screening for most men since
>> it is largely non-specific. That test is what leads to the biopsies. Less
>> screening = fewer biopsies = less revenue.
>>
>> Tim Morken
>>
>>
>>
>&g
histonet-boun...@lists.utsouthwestern.edu
[mailto:histonet-boun...@lists.utsouthwestern.edu] On Behalf Of Morken, Timothy
Sent: Wednesday, 11 April 2012 7:49 AM
To: Kim Donadio
Cc: Histonet
Subject: RE: [Histonet] In House Labs in WSJ
>From the New York Times:
1)
U.S. Panel Says No to Prost
to the biopsies. Less
> screening = fewer biopsies = less revenue.
>
> Tim Morken
>
>
>
> -Original Message-
> From: histonet-boun...@lists.utsouthwestern.edu
> [mailto:histonet-boun...@lists.utsouthwestern.edu] On Behalf Of Daniel
> Schneider
> Sent: Tu
iopsies = less revenue.
>
> Tim Morken
>
>
>
> -Original Message-
> From: histonet-boun...@lists.utsouthwestern.edu
> [mailto:histonet-boun...@lists.utsouthwestern.edu] On Behalf Of Daniel
> Schneider
> Sent: Tuesday, April 10, 2012 11:22 AM
> To: Histonet
Sent: Tuesday, April 10, 2012 11:22 AM
To: Histonet
Subject: [Histonet] In House Labs in WSJ
The Wall Street Journal served up a timely article for us.
You'll see both sides of the argument below. One side is right.
DLS
HEALTH INDUSTRY
April 9, 2012, 7:22 p.m. ET
Prostate-Test Fees Challenge
The Wall Street Journal served up a timely article for us.
You'll see both sides of the argument below. One side is right.
DLS
HEALTH INDUSTRY
April 9, 2012, 7:22 p.m. ET
Prostate-Test Fees Challenged
By CHRISTOPHER WEAVER
Doctors in urology groups that profit from tests for prostate cancer
orde